RxDoctor Payments Data

Kelly Carr

Family · Lawrenceville, PANPI 1154344257

Payments from drug & device makers

$1,137in general payments, 2019–2025

Across 69 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$160
  • Novo Nordisk$158
  • Lilly USA, LLC$157
  • AstraZeneca$130
  • AbbVie$114
  • Johnson & Johnson$71
  • plus $347 from 10 others

What the payments were for

  • Food & beverage$1,11498%
  • Education$232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,137 in reported general payments places this provider in the 75th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$225
Medicare patients
18
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide40$42,490
OzempicSemaglutide31$39,873
JardianceEmpagliflozin33$32,360
EliquisApixaban27$31,945
MounjaroTirzepatide17$27,779
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$22,931
OxycontinOxycodone Hcl16$21,235
JanuviaSitagliptin Phosphate18$19,833
Spiriva RespimatTiotropium Bromide11$16,392
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$12,080
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,976
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$9,392
Humalog Kwikpen U-100Insulin Lispro15$8,862
XareltoRivaroxaban12$7,603
ErythromycinErythromycin Base14$6,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$157$70,26957 claims
Boehringer IngelheimJardiance, Spiriva Respimat$28$48,75244 claims
Novo NordiskOzempic$158$39,87331 claims
PfizerEliquis, Premarin$70$36,82244 claims
GSKAnoro Ellipta, Trelegy Ellipta$160$32,90750 claims
Johnson & JohnsonXarelto$71$7,60312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,717 family providers in Pennsylvania.

Other family in Lawrenceville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →